12 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 8 Phase 1, 4 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Terminated 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 4 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow Annexon, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument - Geographic Atrophy | Phase 3 | Not yet recruiting | Annexon, Inc. | 605 | 2026-09-30 | 2026-09-08 |
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Tanruprubart - Guillain-Barre Syndrome | Phase 3 | Recruiting | Annexon, Inc. | 30 | 2025-09-12 | 2026-10-26 |
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument, Sham Administration - Geographic Atrophy | Phase 3 | Active not recruiting | Annexon, Inc. | 659 | 2024-07-30 | 2026-10-06 |
| A Study of ANX009 in Adult Participants With Lupus Nephritis ANX009 - Lupus Nephritis | Phase 1 | Completed | Annexon, Inc. | 7 | 2022-08-09 | 2024-08-22 |
| Dose Study of ANX1502 in Healthy Volunteers ANX1502, Placebo - Healthy | Phase 1 | Completed | Annexon, Inc. | 135 | 2022-06-27 | 2024-12-27 |
| Single Ascending Dose Study of ANX105 ANX105, Placebo - Healthy | Phase 1 | Completed | Annexon, Inc. | 23 | 2022-02-28 | 2024-08-19 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) ANX005 - Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 2 | Completed | Annexon, Inc. | 7 | 2021-11-10 | 2026-06-30 |
| A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy ANX007, Sham comparator - Geographic Atrophy | Phase 2 | Completed | Annexon, Inc. | 270 | 2021-02-26 | 2026-10-21 |
| Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) ANX005 - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Annexon, Inc. | 17 | 2021-01-15 | 2025-01-06 |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome ANX005, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Annexon, Inc. | 242 | 2020-12-17 | 2025-05-29 |
| A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) ANX009, Placebo - Safety and Tolerability in Healthy Volunteers | Phase 1 | Completed | Annexon, Inc. | 48 | 2020-10-30 | 2021-08-30 |
| An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease ANX005 - Huntington Disease | Phase 2 | Completed | Annexon, Inc. | 28 | 2020-09-29 | 2026-08-25 |
| A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) ANX005, Intravenous immunoglobulin - Guillain-Barré Syndrome | Phase 1 | Completed | Annexon, Inc. | 14 | 2020-01-29 | 2021-08-11 |
| Study of ANX007 in Participants With Primary Open-angle Glaucoma 2.5mg ANX007, 5.0mg ANX007, Sham Procedure - Open Angle Glaucoma | Phase 1 | Completed | Annexon, Inc. | 17 | 2018-07-25 | 2020-08-20 |
| Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma ANX007 - Open-angle Glaucoma | Phase 1 | Completed | Annexon, Inc. | 9 | 2018-03-23 | 2020-08-20 |
| Single Dose Study of ANX005 in Healthy Volunteers ANX005, IVIg, Placebos - Safety and Tolerability in Healthy Volunteers | Phase 1 | Terminated | Annexon, Inc. | 27 | 2016-12-01 | 2020-08-20 |
Geographic Atrophy (3) · Guillain-Barre Syndrome (3) · Glaucoma, Open-Angle (2) · Amyotrophic Lateral Sclerosis (1) · Huntington Disease (1) · Lupus Nephritis (1)
Immunoglobulins, Intravenous (2) · Immunoglobulin Fab Fragments (1) · Immunoglobulin G (1)
United States (9) · Australia (5) · Netherlands (3) · Austria (2) · Bangladesh (2) · Canada (2) · Denmark (2) · France (2) · New Zealand (2) · Philippines (2) · Spain (2) · United Kingdom (2) · Bulgaria (1) · Czechia (1) · Germany (1)
Eric Humphriss (2) · Benjamin Hoehn, MD (1) · Benjamin Hoehn, MD, PhD (1) · Eric Humphriss, MBA (1) · Jason Lickliter, MBBS PhD (1) · Olga Bandman (1) · Olga Bandman, MD (1) · Sandy Calman, MD (1)
2025 (1)